Vimarsana
Biggest News Aggregation in the World

Page 32 - New Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from New Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In New Phase Today - Breaking & Trending Today

Regeneron antibody cocktail 'helps prevent' symptomatic Covid-19: Drugmaker - Vimarsana News

Regeneron antibody cocktail 'helps prevent' symptomatic Covid-19: Drugmaker

Regeneron antibody cocktail 'helps prevent' symptomatic Covid-19: Drugmaker ANI | Updated: Apr 13, 2021 06:10 IST New York [US], April 13 (ANI): New Phase 3 trial data finds a single shot of Regeneron's Covid-19 antibody cocktail was able to prevent symptomatic Covid-19 among people exposed to the virus, the company said on Monday. Regeneron, in its statement, said that it will seek expansion of the emergency use authorization for the drug, which is currently available in the United States to treat mild-to-moderate Covid-19 in people already infected with...

Source: aninews.in
New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years - Vimarsana News

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years

Share this article SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/ --  The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2 a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA ® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112). 1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-relate...

Free2Move Deploys MOBILITY CARD - Vimarsana News

Free2Move Deploys MOBILITY CARD

Free2Move Deploys MOBILITY CARD Free2Move Deploys MOBILITY CARD, a Mobility Account and Its Universal Payment Card to Simplify the Implementation of Mobility Packages for Companies Tuesday, March 2, 2021 12:02 PM Available beginning March 1st 2021, MOBILITY CARD is Free2Move's new mobility offer dedicated to businesses. 100% customizable and flexible, it simplifies employee travel throughout Europe. MOBILITY CARD is based on a dedicated mobility account, an application to manage employee expenses according to their profiles and a payment card facilitating all types of transport: fuel, electr...

The Man Who Refused to Bow - Vimarsana News

The Man Who Refused to Bow

The Atlantic Adam Kinzinger says he’ll fight to take his party back from Donald Trump. February 27, 2021 Adam Maida/ Tom Williams / Brendan Smialowski/ Getty / The Atlantic adam Kinzinger is a liberated individual—liberated from his party leadership, liberated from the fear of being beaten in a primary, liberated to speak his mind. The 43-year-old representative was one of 10 House Republicans who voted to impeach Donald Trump for inciting the attack on the U.S. Capitol. “I don’t have a constitutional duty to defend against a guy that is a jerk and maybe says some things I don’t lik...

Covid-19: 'Next phase of vaccination to start soon' - The Hindu BusinessLine - Vimarsana News

Covid-19: 'Next phase of vaccination to start soon' - The Hindu BusinessLine

Seniors and those with co-morbidities will get priority; pvt sector to play key role: Health Sec